Zura Bio (ZURA) Long-Term Investments (2021 - 2022)
Zura Bio's (ZURA) quarterly Long-Term Investments came in at $141.5 million in Q4 2022, up 1.49% year-on-year from $139.4 million in Q4 2021, and up 0.85% quarter-over-quarter from $140.3 million in Q3 2022.
Zura Bio (ZURA) Long-Term Investments (2021 - 2022) Analysis & Trends
Zura Bio's Long-Term Investments history runs 2 years deep, the most recent figure standing at $141.5 million for Q4 2022.
- On a quarterly basis, Long-Term Investments rose 1.49% year-over-year to $141.5 million in Q4 2022; TTM through Dec 2022 was $141.5 million, a 1.49% increase from a year earlier, with the FY2022 full-year figure at $141.5 million, up 1.49% from the prior year.
- Long-Term Investments grew to $141.5 million in Q4 2022 per ZURA's latest filing, from $140.3 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $141.5 million in Q4 2022 and bottomed at $139.4 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | 505,194.89 |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Zura Bio | 610.49 Mn | 610.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 141.47 Mn |
| Sep 30, 2022 | 140.28 Mn |
| Jun 30, 2022 | 139.60 Mn |
| Mar 31, 2022 | 139.42 Mn |
| Dec 31, 2021 | 139.40 Mn |